Strategic Advances in EGFR+ NSCLC: Navigating Evolving Treatment Paths With Dato-DXd

Jacob Sands, MD, discusses the inclusion of Dato-DXd into the treatment landscape of EGFR-mutant NSCLC.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.